Mlrqueue

Emerging biotech teams produce investor decks, conference materials, partner outreach and other external content before they have a large internal medical, legal and regulatory review function. The supplied research found enterprise review software and service firms, but no verified two-sided marketplace centered on smaller teams. That gap is plausible; it also carries confidentiality, qualification, conflict and liability risk.

Mlrqueue accepts content only from an authorized organization, records intended audience, market, product status, claims, references and deadline, then runs a cited prescreen. The result is a list of review candidates, never approval. A coordinator or rules engine proposes reviewers whose verified discipline, jurisdiction, therapeutic experience, availability and conflict declarations match the assignment. The buyer chooses the reviewer and scope.

Draft, finding, author response, medical decision, legal decision, regulatory decision, approval, release and later correction remain separate. A marketplace completion signal cannot authorize publication. Reviewer credentials require evidence and expiry; confidentiality boundaries and work-product ownership require explicit agreements.

The first release should focus on one material class and one market, with a curated reviewer bench rather than an open marketplace. Its job is to shorten intake and coordination while preserving accountable human judgment.

Regulatory operations, medical affairs, legal or commercial operations leader at an emerging biotech company or specialist life-sciences agency